Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.46 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.46 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3673025 | 0.97 | ALOX15 (0.57) | ALOX15GNAI3GNAO1GNAI1CARM1 | |
| SCHEMBL13547359 | 0.91 | ALOX15 (0.50) | ALOX15GNAI3GNAO1GNAI1CARM1 | |
| SCHEMBL21214177 | 0.91 | ALOX15 (0.50) | ALOX15GNAI3GNAO1GNAI1CARM1 | |
| SCHEMBL3966764 | 0.85 | GNAI3 (0.59) | ALOX15GNAI3GNAO1GNAI1SPHK1 | |
| SCHEMBL21214215 | 0.85 | — | — | |
| SCHEMBL12838075 | 0.85 | — | — | |
| SCHEMBL508627 | 0.84 | ALOX15 (0.60) | ALOX15GNAI3GNAO1GNAI1CARM1 | |
| Hydrochloric Acid SCHEMBL3668361 | 0.83 | GNAI3 (0.62) | ALOX15GNAI3GNAO1GNAI1SPHK1 | |
| Hydrochloric Acid SCHEMBL14311820 | 0.83 | ALOX15 (0.46) | ALOX15GNAI3GNAO1GNAI1CARM1 | |
| Hydrochloric Acid SCHEMBL15808683 | 0.83 | ALOX15 (0.46) | ALOX15GNAI3GNAO1GNAI1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | claimed |
| CN-1212696-A | Pyrimido [5, 4-d ] pyrimidines, medicaments containing these compounds, their use and processes for their preparation | THOMAE GMBH DR K (DE) | 1999-03-31 | — | — | CN | claimed |
| CN-115064645-B | Preparation method of dispersing agent, quantum dot dispersion liquid and infrared detector | 华中科技大学 | 2026-02-27 | — | — | CN | disclosed |
| WO-2022008475-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2022-01-13 | — | — | WO | disclosed |
| EP-3475277-B1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-10-20 | — | — | EP | disclosed |
| WO-2021180103-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-09-16 | — | — | WO | disclosed |
| EP-2536483-B1 | SOLVENT TREATMENT PROCESS | COMMW SCIENT IND RES ORG (AU) | 2017-05-31 | — | — | EP | disclosed |
| WO-2015177326-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| US-20130053614-A1 | SOLVENT TREATMENT PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (AU) | 2013-02-28 | — | — | US | disclosed |
| US-20130053614-A1 | SOLVENT TREATMENT PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (AU) | 2013-02-28 | — | — | US | disclosed |
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-04-05 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2037951-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | Sirion Therapeutics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
| US-7173054-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | disclosed |
| CN-1212696-A | Pyrimido [5, 4-d ] pyrimidines, medicaments containing these compounds, their use and processes for their preparation | THOMAE GMBH DR K (DE) | 1999-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | ALOX15 1969/4885GNAI3 2135/4885GNAO1 1741/4885 |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | ALOX15 1715/4885GNAI3 1816/4885GNAO1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.